Evidence map›Paper›PMID 38016765›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].

X R Yang, H C Sun, Q Xie, W G Zhang, W D Jia, M Zhao, H T Zhao, X F Liu, L D Zhou, S Yan and 6 more

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

X R YangDepartment of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
H C SunDepartment of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Q XieDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
W G ZhangHepatic Surgery Center,Tongji Hospital,Tonji Medical College, Huazhong University of Science and Technolog, Wuhan 430030, China.
W D JiaDepartment of Liver Surgery, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
M ZhaoDepartment of Minimally Invasive and Interventional, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China.
H T ZhaoDepartment of Hepatic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
X F LiuDepartment of Oncology, Qinhuai Medical District, Eastern Theater General Hospital of PLA, Nanjing 210002, China.
L D ZhouDepartment of Liver Surgery, Xiangya Hospital of Central South University, Changsha 410008, China.
S YanDepartment of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
L XuDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
N Y WangDepartment of Cancer Center, the First Hospital of Jilin University, Changchun 130021, China.
Y DingDepartment of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
X D ZhuDepartment of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
J ZhouDepartment of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
J FanDepartment of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Fudan University · CNSecond Affiliated Hospital of Zhejiang University · CNSun Yat-sen University · CN81th Hospital of PLA · CNCentral South University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNJilin University · CNRuijin Hospital · CNTongji Hospital · CNUniversity of Science and Technology of China · CN

Funding

National Nature Science Foundation of China 82072715Shanghai Municipal Health 2019CXJQ02
6 · The paper itself

Abstract

Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4, 2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsChinaHumansPhenylurea CompoundsPractice Guidelines as TopicQuinolinesVascular Endothelial Growth Factor AAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolinesVascular Endothelial Growth Factor AHepatocellular carcinomaLenvatinibLiver neoplasmsOverall managementReasonable applicationSafetySystemic treat-ment

Identifiers

PMID38016765
PMCPMC12813812
OpenAlexW4389152588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.